Vantage takes a look at the sellside’s naughty and nice list for 2018: prospects improved considerably for Merck & Co’s Keytruda and Abbvie’s Mavyret, the latter…
Lilly reduces its reliance on older products, but Roche and Sanofi still need fresh blood.
If big biotech cannot deliver innovation investors might start demanding shareholder payout plans that look more like big pharma's.
Celgene’s Revlimid ranks as biopharma’s most contested blockbuster, with a huge spread in future sales forecasts, while drugs from Bristol-Myers Squibb and Sanofi also…
Pipeline projects are forecast to contribute a substantial proportion of future sales at Abbvie and Lilly, though the same cannot be said for all big drug developers.
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
Other therapy areas take a back seat as the pharma industry continues to focus on cancer-focused licensing deals.
Licensing deal activity holds up in first half of 2018 as biopharma continues to stay away from takeovers.
Celgene's CAR-T and Glaxosmithkline's antibody-drug conjugate are among the industry's most valuable R&D assets.